Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: PH stock price vs JNJ: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at JNJ's multiple
Needs JNJ P/E.
Implied fair value · at PH's multiple
Needs PH P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
17 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
PARKER-HANNIFIN CORPORATION · implied price per share
Bear
$271.45
Base
$330.29
Bull
$406.93
Johnson & Johnson · implied price per share
Bear
$76.44
Base
$92.02
Bull
$112.30
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
HONEYWELL INTERNATIONAL INC
PH vs HON
NORDSON CORP
PH vs NDSN
Eaton Corp plc
PH vs ETN
EMERSON ELECTRIC CO
PH vs EMR
DANAHER CORP /DE/
PH vs DHR
ILLINOIS TOOL WORKS INC
PH vs ITW
Pfizer Inc.
PH vs PFE
Eli Lilly and Company
PH vs LLY
Abbott Laboratories
PH vs ABT
Amgen Inc.
PH vs AMGN
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe PH can sustain its high ROIC and quality scores while reaccelerating growth, then hold or accumulate selectively because the business quality is strong enough to justify part of the premium; otherwise, the rich P/E and EV/EBITDA versus JNJ argue for caution given the 37.3% downside implied by the valuation model.
PH trades at a meaningful premium to JNJ on earnings and EBITDA metrics, and the implied price of $625.53 suggests 37.3% downside versus the current $997.52 price. However, JNJ-implied range and historical band both sit closer to current levels than the DCF range, creating a valuation conflict.
Supporting Metrics
